Study of Cerebral Tissue Oxygenation During Transfusion in Traumatic Brain Injury
NCT ID: NCT01728831
Last Updated: 2015-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2012-11-30
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Hypothesis:
• Improved oxygen delivery causes improved brain tissue oxygen saturation.
Testable Hypothesis:
• The transfusion of packed red blood cells resulting in a change in the hemoglobin in the 70- 100g/L range, will be associated with an increase in cerebral tissue oxygen saturation measured by near infrared spectroscopy in severe traumatic brain injured patients.
Primary Aims:
• Evaluate the applicability of a 4 wavelength near-infrared spectroscopy (NIRS) to monitor the cerebral oximetry in traumatic brain injury patients. Observe the trend of cerebral tissue oxygenation saturations (StO2) before, during and after a blood transfusion in TBI patients.
Secondary Hypothesis:
* We hypothesize that as pRBCs are transfused there will be a plateau (i.e. hemoglobin threshold) beyond which no increase in cerebral tissue oxygenation will occur.
* There will be lag time between the increase in systemic hemoglobin and the improvement of cerebral tissue oxygenation.
Secondary Aims:
* To correlate the systemic hemoglobin level with cerebral tissue oxygenation saturation as pRBCs are transfused.
* Correlation of non-invasive cerebral tissue oxygenation saturation measurements with invasive brain tissue oxygen tension (if available).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient with clinical diagnosis of severe TBI and GCS \<9
3. Patient requiring PRBC transfusion with a qualifying Hb\< 10/dL
Exclusion Criteria
2. Deficient signal of SctO2 impeding its proper valuation
3. Active coronary ischemia as judged by dynamic ischemic ECG changes and/ or positive troponin levels not due to myocardial contusion.
4. Active hemorrhage: Example
1. Bleeding into the chest, abdomen or retro-peritoneum likely to require surgery +/- embolization
2. Pelvic fracture likely to require surgery +/- embolization
3. More than two long bone fractures requiring operative fixation
5. Clinical diagnosis of drug or alcohol intoxication as predominant cause of coma
6. Systolic BP \<90mmHg
7. Heart rate \> 120bpm
8. GCS=3 + un-reactive pupils
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Physicians' Services Incorporated Foundation
OTHER
Unity Health Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Baker, MD
Role: STUDY_DIRECTOR
Medical Director, Critical Care
Victoria A McCredie, MBChB
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Center, University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Michael's Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-294
Identifier Type: -
Identifier Source: org_study_id